Markets

Cytokinetics (CYTK) Looks Strong: Stock Gains 17.2% - Tale of the Tape

Cytokinetics ( CYTK ) as a big mover last session, as the company saw its shares surge over 17 % on the day. This rally higher can be attributable to solid volume with far more shares changing hands than in a normal session. This stock, trading in a volatile price range of $3.66 to $4.52 in the past one-month time frame, showed a pick-up yesterday at $4.29.

Although the company has seen no estimate revisions in the past one month, its Zacks Consensus Estimate of a loss narrowed over the same period, suggesting that more solid trading could be ahead for the company. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.

Cytokinetics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Other attractive players in the med-biomed industry include Heska Corporation ( HSKA ), Illumina Inc. ( ILMN ) and Cambrex Corporation. ( CBM ) all carrying a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CYTOKINETCS INC (CYTK): Free Stock Analysis Report

HESKA CORP (HSKA): Free Stock Analysis Report

ILLUMINA INC (ILMN): Free Stock Analysis Report

CAMBREX CORP (CBM): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CYTK HSKA ILMN

Other Topics

Investing Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More